Johnson & Johnson buy Buzzelmann
Summary
This prediction ended on 18.01.19 with a price of €116.44. With a performance of 1.47%, the BUY prediction by Buzzelmann for Johnson & Johnson closed with a slight gain. Buzzelmann has 50% into this predictionJohnson Johnson is a multinational company that focuses on the development, manufacturing, and marketing of a wide range of consumer health products, medical devices, and pharmaceuticals. The company was founded in 1886 and is headquartered in New Jersey, USA. It operates in more than 60 countries and has a diverse portfolio of popular brands including Band-Aid, Tylenol, and Neutrogena. As of 2021, Johnson Johnson has a market capitalization of over $435 billion and is listed on the New York Stock Exchange under the symbol JNJ.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Johnson & Johnson | 0.956% | 0.956% | -1.421% | 5.442% |
iShares Core DAX® | -1.471% | 1.895% | 25.178% | 22.236% |
iShares Nasdaq 100 | -0.486% | 4.395% | 29.415% | 42.175% |
iShares Nikkei 225® | -2.115% | 2.450% | 20.561% | 6.454% |
iShares S&P 500 | 0.394% | 3.118% | 29.456% | 42.672% |
Comments by Buzzelmann for this prediction
In the thread Johnson & Johnson diskutieren
Buzzelmann stimmt der Buy-Einschätzung von Maxi-Scalibusa zu
Buzzelmann stimmt am 17.07.2018 der Buy-Einschätzung von Maxi-Scalibusa mit dem Kursziel 190,5$ zu.
Überschrift: Johnson & Johnson